ADCs (Everic© lyo & amber)
Products
Information
Unlock the potential of ADC packaging that safeguards every molecule. Antibody-drug conjugates (ADCs) are a fast-growing class of biopharmaceuticals, projected to reach €53 billion by 2030 with over 3,000 active patents by 2025 (GlobalData, May 2025). Their complex structure - monoclonal antibody, linker, and cytotoxic payload - enables targeted cancer therapy but demands packaging that ensures stability, safety, and efficacy. EVERIC(R) amber vials provide ideal primary packaging for light-sensitive products like ADCs and other biologics. Paired with EVERIC(R) lyo vials, they create optimal conditions for lyophilized products, preventing fogging and improving residual emptying. Suitable for both bulk and ready-to-use applications, EVERIC(R) lyo & amber delivers reliability throughout the drug lifecycle.
Main Category
Primary Packaging (Packaging Materials and Equipment) (Products)Packaging Materials and Equipment (Products)
Category
Primary Packaging (Primary Packaging)Packaging Materials and Equipment (Products)
Available In
OceaniaNorth America (USA, Canada)AfricaMiddle East Region (e.g. UAE)Central America (e.g. Mexico)East Asia (e.g. China, Japan, Korea)Europe - EU countriesEurope - non EU (e.g. UK, Russia, ex-CIS countries)South America (e.g. Brazil, Colombia)South Asia (e.g. India, Pakistan, Sri Lanka)South East Asia (e.g. Thailand, Philippines, Singapore)
